Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2023 - 2025)

Zhengye Biotechnology Holding has reported Cash & Equivalents over the past 3 years, most recently at $7.1 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 173.97% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, up 173.97% year-over-year, with the annual reading at $7.2 million for FY2025, 170.46% up from the prior year.
  • Cash & Equivalents was $7.1 million for Q4 2025 at Zhengye Biotechnology Holding, up from $2.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $7.1 million in Q4 2025 and troughed at $2.6 million in Q4 2024.
  • The 3-year median for Cash & Equivalents is $3.2 million (2023), against an average of $4.0 million.
  • Year-over-year, Cash & Equivalents tumbled 31.4% in 2024 and then skyrocketed 173.97% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $3.8 million in 2023, then plummeted by 31.4% to $2.6 million in 2024, then skyrocketed by 173.97% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Cash & Equivalents are $7.1 million (Q4 2025), $2.6 million (Q2 2025), and $2.6 million (Q4 2024).